Please login to the form below

Not currently logged in

Kite Pharma once again looks to Amgen

William Go and Jeff Aycock fourth and fifth senior figures to join from Amgen this year

Kite Pharma has appointed two former Amgen directors to senior positions in its research team.

Dr William Go joins as senior director, clinical development, and Jeff Aycock joins as senior director, clinical operations. 

Dr Go was most recently US medical lead for Amgen's cancer treatments Vectibix (panitumumab) and medical director in the company's global development business. Aycock, meanwhile, was most recently director, oncology study management and US regional lead at Amgen, overseeing five oncology programmes.

The two will now add their expertise in cancer to Kite as it plans to advance its immunotherapy plans in oncology.

They are the fourth and fifth senior figures to make their way from Amgen to Kite this year, following the appointments of VP, clinical development, Dr Jeffrey Wiezorek in May and of chief medical officer Dr David Chang earlier this month to replace Dr Keith Nolop who spent just one year in the role.

Outside R&D, Kite also added Dr Rizwana Sproule from Amgen as head VP, regulatory affairs in January.

24th June 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....